Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR 2nd, Azad N, Kopetz S.

Ann Oncol. 2018 Jul 3. doi: 10.1093/annonc/mdy221. [Epub ahead of print] No abstract available.

PMID:
29982323
2.

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M.

J Hematol Oncol. 2018 May 30;11(1):71. doi: 10.1186/s13045-018-0616-2.

3.

Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials.

Overman MJ, Ellis LM, Joffe S.

JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.1002. [Epub ahead of print] No abstract available.

PMID:
29799989
4.

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.

Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG.

Front Oncol. 2018 Apr 20;8:107. doi: 10.3389/fonc.2018.00107. eCollection 2018. Review.

5.

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.

Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K.

J Natl Cancer Inst. 2018 Apr 27. doi: 10.1093/jnci/djy067. [Epub ahead of print]

PMID:
29718453
6.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

PMID:
29668571
7.

Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.

Mehrvarz Sarshekeh A, Overman MJ, Kopetz S.

Future Oncol. 2018 Feb 23. doi: 10.2217/fon-2017-0696. [Epub ahead of print]

PMID:
29473436
8.

Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.

Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, Cloyd J, Wang H, Maitra A, Wolff RA, Varadhachary G, Overman MJ, Lee JE, Fleming JB, Tzeng CW, Katz MH, Holliday EB, Krishnan S, Minsky BD, Herman JM, Taniguchi CM, Das P, Crane CH, Le O, Bhosale P, Tamm EP, Koay EJ.

Cancer. 2018 Apr 15;124(8):1701-1709. doi: 10.1002/cncr.31251. Epub 2018 Jan 25.

9.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

PMID:
29355075
10.

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.

Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S.

J Natl Cancer Inst. 2018 Jan 15. doi: 10.1093/jnci/djx288. [Epub ahead of print]

PMID:
29346573
11.

Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.

Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ.

Oncologist. 2018 Mar;23(3):277-e26. doi: 10.1634/theoncologist.2017-0568. Epub 2017 Dec 19.

12.

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e103-e108. doi: 10.1016/j.clml.2017.11.001. Epub 2017 Nov 14.

PMID:
29196178
13.

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S.

Clin Cancer Res. 2018 Mar 1;24(5):1062-1072. doi: 10.1158/1078-0432.CCR-17-2484. Epub 2017 Nov 27.

PMID:
29180604
14.

Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.

Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S.

Gut. 2018 Jun;67(6):1095-1102. doi: 10.1136/gutjnl-2017-313786. Epub 2017 Oct 30.

PMID:
29084828
15.

Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?

Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Marchal F, Conrad C, Aloia TA, Vauthey JN, Chun YS; BIG-RENAPE Working Group.

Ann Surg Oncol. 2018 Jan;25(1):179-187. doi: 10.1245/s10434-017-6141-7. Epub 2017 Oct 25.

PMID:
29071660
16.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R 2nd, Azad N, Kopetz S.

Ann Oncol. 2018 Jan 1;29(1):139-144. doi: 10.1093/annonc/mdx688.

PMID:
29069279
17.

Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.

Yamashita S, Overman MJ, Wang H, Zhao J, Okuno M, Goumard C, Tzeng CW, Kim M, Fleming JB, Vauthey JN, Katz MH, Lee JE, Conrad C.

Ann Surg Oncol. 2017 Dec;24(13):3954-3963. doi: 10.1245/s10434-017-6098-6. Epub 2017 Oct 4.

18.

Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade.

Grotz TE, Royal RE, Mansfield PF, Overman MJ, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF.

World J Gastrointest Oncol. 2017 Sep 15;9(9):354-362. doi: 10.4251/wjgo.v9.i9.354.

19.

4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C.

Clin Cancer Res. 2017 Dec 1;23(23):7263-7275. doi: 10.1158/1078-0432.CCR-17-0831. Epub 2017 Sep 25.

PMID:
28947567
20.

Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm.

Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ.

Ann Surg Oncol. 2017 Nov;24(12):3667-3672. doi: 10.1245/s10434-017-6052-7. Epub 2017 Aug 22.

PMID:
28831698
21.

Underreporting of Research Biopsies from Clinical Trials in Oncology.

Parseghian CM, Raghav K, Wolff RA, Ensor J Jr, Yao J, Ellis LM, Tam AL, Overman MJ.

Clin Cancer Res. 2017 Nov 1;23(21):6450-6457. doi: 10.1158/1078-0432.CCR-17-1449. Epub 2017 Jul 28.

PMID:
28754815
22.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.

Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.

PMID:
28734759
23.

Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.

Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG.

JAMA Surg. 2017 Nov 1;152(11):1048-1056. doi: 10.1001/jamasurg.2017.2227.

PMID:
28700784
24.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.

Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF.

Ann Surg Oncol. 2017 Sep;24(9):2646-2654. doi: 10.1245/s10434-017-5938-8. Epub 2017 Jul 10.

PMID:
28695394
25.

Genomic Profiling of Small-Bowel Adenocarcinoma.

Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ.

JAMA Oncol. 2017 Nov 1;3(11):1546-1553. doi: 10.1001/jamaoncol.2017.1051.

PMID:
28617917
26.

Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery.

Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ.

BMC Cancer. 2017 May 15;17(1):331. doi: 10.1186/s12885-017-3327-0.

27.

Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?

Vauthey JN, Mizuno T, Overman MJ, Soubrane O.

J Hepatol. 2017 Jul;67(1):10-11. doi: 10.1016/j.jhep.2017.04.011. Epub 2017 May 3. No abstract available.

PMID:
28476639
28.

Modeling of Patient-Derived Xenografts in Colorectal Cancer.

Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S.

Mol Cancer Ther. 2017 Jul;16(7):1435-1442. doi: 10.1158/1535-7163.MCT-16-0721. Epub 2017 May 3.

29.

FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.

Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A.

Oncotarget. 2017 Jun 13;8(24):39268-39279. doi: 10.18632/oncotarget.16848.

30.

Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.

Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S.

Clin Cancer Res. 2017 Aug 15;23(16):4578-4591. doi: 10.1158/1078-0432.CCR-17-0232. Epub 2017 Apr 11.

PMID:
28400427
31.

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.

Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S.

Clin Cancer Res. 2017 Aug 1;23(15):4146-4154. doi: 10.1158/1078-0432.CCR-16-3138. Epub 2017 Mar 9.

PMID:
28280091
32.

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.

Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S.

PLoS One. 2017 Mar 7;12(3):e0173345. doi: 10.1371/journal.pone.0173345. eCollection 2017. Erratum in: PLoS One. 2017 May 17;12 (5):e0178275.

33.

Glycemia but not the Metabolic Syndrome is Associated with Cognitive Decline: Findings from the European Male Ageing Study.

Overman MJ, Pendleton N, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Rastrelli G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean MEJ, Punab M, Lee DM, Correa ES, Ahern T, Laurent MR, Verschueren SMP, Antonio L, Gielen E, Rutter MK, Vanderschueren D, Wu FCW, Tournoy J; EMAS study group.

Am J Geriatr Psychiatry. 2017 Jun;25(6):662-671. doi: 10.1016/j.jagp.2017.02.004. Epub 2017 Feb 7.

PMID:
28259698
34.

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.

Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H.

Ann Oncol. 2017 Apr 1;28(4):741-747. doi: 10.1093/annonc/mdx004.

35.

Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity.

Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P.

Radiother Oncol. 2017 Jan;122(1):146-151. doi: 10.1016/j.radonc.2016.12.015. Epub 2017 Jan 3.

PMID:
28057329
36.

Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.

Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ.

Cancer. 2017 May 15;123(6):1011-1017. doi: 10.1002/cncr.30445. Epub 2016 Nov 14.

37.

Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.

Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH.

J Gastrointest Surg. 2016 Dec;20(12):1975-1985. Epub 2016 Oct 11.

PMID:
27730398
38.

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S.

Cancer Discov. 2016 Dec;6(12):1352-1365. Epub 2016 Oct 11.

39.

Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.

Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru D, Overman MJ, Brudvik KW, Conrad C, Aloia TA, Vauthey JN.

Surgery. 2017 Feb;161(2):332-340. doi: 10.1016/j.surg.2016.07.032. Epub 2016 Aug 31.

PMID:
27592215
40.

Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma.

Overman MJ, Soifer HS, Schueneman AJ, Ensor J Jr, Adsay V, Saka B, Neishaboori N, Wolff RA, Wang H, Schnabel CA, Varadhachary G.

BMC Cancer. 2016 Aug 22;16:668. doi: 10.1186/s12885-016-2677-3.

41.

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin.

Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S.

Oncotarget. 2016 Oct 11;7(41):67495-67506. doi: 10.18632/oncotarget.11317.

42.

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon.

Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S.

Oncotarget. 2016 Aug 23;7(34):54627-54631. doi: 10.18632/oncotarget.10559.

43.

Evaluation of cognitive subdomains, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D in the European Male Ageing Study.

Overman MJ, Pendleton N, O'Neill TW, Bartfai G, Casanueva FF, Finn JD, Forti G, Rastrelli G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean MEJ, Punab M, Lee DM, Correa ES, Ahern T, Verschueren SMP, Antonio L, Gielen E, Rutter MK, Vanderschueren D, Wu FCW, Tournoy J; EMAS Study Group.

Eur J Nutr. 2017 Sep;56(6):2093-2103. doi: 10.1007/s00394-016-1247-4. Epub 2016 Jul 1.

PMID:
27370643
44.

Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.

Passot G, Chun YS, Kopetz SE, Overman MJ, Conrad C, Aloia TA, Vauthey JN.

Eur J Surg Oncol. 2016 Sep;42(9):1378-84. doi: 10.1016/j.ejso.2016.02.249. Epub 2016 Mar 5.

45.

Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.

Link JT, Overman MJ.

Cancer J. 2016 May-Jun;22(3):190-5. doi: 10.1097/PPO.0000000000000196. Review.

PMID:
27341597
46.

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.

Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang ZQ, Hamilton SR, Kopetz S.

Br J Cancer. 2016 Jun 14;114(12):1352-61. doi: 10.1038/bjc.2016.87. Epub 2016 Jun 7.

47.

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.

Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F.

Mol Cancer Ther. 2016 Jun;15(6):1397-404. doi: 10.1158/1535-7163.MCT-15-0712. Epub 2016 May 20.

48.

Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes.

Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, Wang H, Overman MJ, Varadhachary GR.

PLoS One. 2016 May 12;11(5):e0154985. doi: 10.1371/journal.pone.0154985. eCollection 2016.

49.

Acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine.

Hoffmann MS, Overman MJ, Nates JL.

J Community Support Oncol. 2016 Apr;14(4):178-9. doi: 10.12788/jcso.0187.

PMID:
27152518
50.

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.

Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S.

Ann Oncol. 2016 Jun;27(6):1068-74. doi: 10.1093/annonc/mdw073. Epub 2016 Feb 18.

PMID:
27045102

Supplemental Content

Loading ...
Support Center